Amgen to invest $1 bln in new North Carolina manufacturing site

BY Reuters | ECONOMIC | 12/05/24 09:29 AM EST

Dec 5 (Reuters) -

U.S. drugmaker Amgen (AMGN) said on Thursday it will invest $1 billion in a second manufacturing facility in North Carolina, expanding its prior $550 million commitment to the region.

The new facility, to be built in Holly Springs alongside Amgen's (AMGN) existing site, will create 370 new jobs.

The company did not immediately respond to a request for comment on what treatments it was planning to manufacture at the new site.

Amgen's (AMGN) first Holly Springs facility supports both conventional and new technologies of production, allowing Amgen (AMGN) to make multiple products in the same plant, according to a regulatory filing.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Tasim Zahid)

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article